# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barrington Research analyst Michael Petusky reiterates Surmodics (NASDAQ:SRDX) from Market Perform to Market Perform.
Fiscal Year 2025 Financial GuidanceSurmodics is increasing its fiscal 2025 total revenue to a range of $116.5 million to $118.5...
Needham analyst Mike Matson reiterates Surmodics (NASDAQ:SRDX) from Hold to Hold.